BRPI0407708A - 3-substituìdo-2(arilalquila)-1-azabicicloalcanos e métodos de seu uso - Google Patents
3-substituìdo-2(arilalquila)-1-azabicicloalcanos e métodos de seu usoInfo
- Publication number
- BRPI0407708A BRPI0407708A BRPI0407708-3A BRPI0407708A BRPI0407708A BR PI0407708 A BRPI0407708 A BR PI0407708A BR PI0407708 A BRPI0407708 A BR PI0407708A BR PI0407708 A BRPI0407708 A BR PI0407708A
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- neurotransmission
- azabicycloalkanes
- arylalkyl
- compounds
- Prior art date
Links
- 125000003710 aryl alkyl group Chemical group 0.000 title abstract 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000005062 synaptic transmission Effects 0.000 abstract 3
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 2
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010029113 Neovascularisation Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- GNVMUORYQLCPJZ-UHFFFAOYSA-M Thiocarbamate Chemical compound NC([S-])=O GNVMUORYQLCPJZ-UHFFFAOYSA-M 0.000 abstract 1
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 abstract 1
- 102000015296 acetylcholine-gated cation-selective channel activity proteins Human genes 0.000 abstract 1
- 108040006409 acetylcholine-gated cation-selective channel activity proteins Proteins 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/372,642 US6953855B2 (en) | 1998-12-11 | 2003-02-21 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| PCT/US2004/005044 WO2004076449A2 (en) | 2003-02-21 | 2004-02-20 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0407708A true BRPI0407708A (pt) | 2006-02-14 |
Family
ID=32926222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0407708-3A BRPI0407708A (pt) | 2003-02-21 | 2004-02-20 | 3-substituìdo-2(arilalquila)-1-azabicicloalcanos e métodos de seu uso |
Country Status (22)
| Country | Link |
|---|---|
| US (11) | US6953855B2 (enExample) |
| EP (1) | EP1594869B9 (enExample) |
| JP (3) | JP4828407B2 (enExample) |
| KR (3) | KR101098490B1 (enExample) |
| CN (2) | CN101220026A (enExample) |
| AT (1) | ATE381563T1 (enExample) |
| AU (1) | AU2004215386B2 (enExample) |
| BR (1) | BRPI0407708A (enExample) |
| CA (1) | CA2514135C (enExample) |
| CY (1) | CY1107175T1 (enExample) |
| DE (1) | DE602004010787T2 (enExample) |
| DK (1) | DK1594869T3 (enExample) |
| EA (1) | EA011033B1 (enExample) |
| ES (1) | ES2300749T3 (enExample) |
| IL (3) | IL169797A (enExample) |
| MX (1) | MXPA05008926A (enExample) |
| NO (3) | NO332757B1 (enExample) |
| NZ (3) | NZ565177A (enExample) |
| PL (3) | PL395717A1 (enExample) |
| PT (1) | PT1594869E (enExample) |
| WO (1) | WO2004076449A2 (enExample) |
| ZA (1) | ZA200506515B (enExample) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| ES2405594T3 (es) * | 2002-09-25 | 2013-05-31 | Memory Pharmaceuticals Corporation | Idazoles, benzotiazoles y benzisotiazoles, y preparación y usos de los mismos |
| WO2005016923A1 (en) | 2003-08-13 | 2005-02-24 | Neurosearch A/S | Novel quinuclidine derivatives and their pharmaceutical use |
| EP1697378B1 (en) * | 2003-12-22 | 2007-11-21 | Memory Pharmaceuticals Corporation | Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof |
| SE0400708D0 (sv) * | 2004-03-22 | 2004-03-22 | Aprea Ab | New compounds and use thereof |
| BRPI0508771A (pt) | 2004-03-25 | 2007-08-14 | Memory Pharm Corp | indazóis, benzotiazóis, benzoisotiazóis, benzisoxazóis, e a preparação e usos dos mesmos |
| US7488737B2 (en) * | 2004-04-22 | 2009-02-10 | Memory Pharmaceutical Corporation | Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof |
| KR20070015607A (ko) * | 2004-05-07 | 2007-02-05 | 메모리 파마슈티칼스 코포레이션 | 1ｈ-인다졸, 벤조티아졸, 1,2-벤조이속사졸,1,2-벤조이소티아졸, 및 크로몬 및 그의 제조법 및 용도 |
| PE20060437A1 (es) | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| RU2418797C2 (ru) * | 2004-12-22 | 2011-05-20 | Мемори Фармасьютиклз Корпорейшн | Лиганды никотинового рецептора альфа-7, их получение и применение |
| US20090012127A1 (en) * | 2005-06-29 | 2009-01-08 | Astrazeneca Ab | Thiophene-2-Carboxamide Derivatives as Alpha 7 Nicotinic Receptor Modulators |
| US20070082939A1 (en) * | 2005-07-26 | 2007-04-12 | Lippa Arnold S | Methods and compositions for the treatment of neuropathies and related disorders |
| CN101248073A (zh) * | 2005-08-22 | 2008-08-20 | 塔加西普特公司 | 杂芳基-取代的二氮杂三环烷类、其制备方法及其应用 |
| US8106066B2 (en) * | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| WO2007038684A2 (en) * | 2005-09-27 | 2007-04-05 | Myriad Genetics, Inc. | Pyrrole derivatives as therapeutic compounds |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| CN101528698A (zh) | 2006-05-09 | 2009-09-09 | 阿斯利康公司 | (2s)-(4e)-n-甲基-5-[3-(5-异丙氧基吡啶)基]-4-戊烯-2-胺的盐形式 |
| TWI389889B (zh) | 2006-05-09 | 2013-03-21 | Targacept Inc | （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型 |
| EP2059238A4 (en) * | 2006-09-07 | 2011-04-06 | Myriad Genetics Inc | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| RU2476220C2 (ru) * | 2007-08-02 | 2013-02-27 | Таргасепт, Инк. | (2s,3r)-n-(2-((3-пиридинил)метил)-1-азабицикло[2.2.2]окт-3-ил)бензофуран-2-карбоксамид, новые солевые формы и способы их применения |
| WO2009029936A1 (en) * | 2007-08-31 | 2009-03-05 | Case Western Reserve University | In vivo imaging of myelin |
| EA019509B1 (ru) | 2007-11-16 | 2014-04-30 | Райджел Фармасьютикалз, Инк. | Карбоксамидные, сульфонамидные и аминовые соединения от метаболических нарушений |
| EP2231666B1 (en) | 2007-12-12 | 2015-07-29 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| US8609730B2 (en) * | 2008-01-08 | 2013-12-17 | The Trustees Of The University Of Pennsylvania | Rel inhibitors and methods of use thereof |
| KR20100113163A (ko) * | 2008-02-13 | 2010-10-20 | 타가셉트 인코포레이티드 | 알파 ７ 니코틴 작용제 및 항정신병제의 조합 |
| US20090239901A1 (en) * | 2008-03-19 | 2009-09-24 | Merouane Bencherif | Method and compositions for treatment of cerebral malaria |
| CN102099357B (zh) | 2008-04-23 | 2014-07-02 | 里格尔药品股份有限公司 | 用于治疗代谢障碍的甲酰胺化合物 |
| WO2009140201A1 (en) * | 2008-05-12 | 2009-11-19 | Targacept, Inc. | Methods for preventing the development of retinopathy by the oral administration of nnr ligands |
| US9155733B2 (en) * | 2008-10-10 | 2015-10-13 | University Of Kentucky Research Foundation | Use of tris-quaternary ammonium salts as pain modulating agents |
| JP5657556B2 (ja) * | 2008-11-11 | 2015-01-21 | ターガセプト，インコーポレイテッド | α７選択的リガンドを用いる治療 |
| CA2744278C (en) | 2008-11-19 | 2015-09-08 | Envivo Pharmaceuticals, Inc. | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
| TW201031664A (en) * | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| RU2011150248A (ru) * | 2009-05-11 | 2013-06-20 | Энвиво Фармасьютикалз, Инк. | Лечение когнитивных расстройств с определенными рецепторами альфа-7 никотиновой кислоты в комбинации с ингибиторами ацетилхолинэстеразы |
| TWI558398B (zh) | 2009-09-22 | 2016-11-21 | 諾華公司 | 菸鹼乙醯膽鹼受體α７活化劑之用途 |
| AR079724A1 (es) * | 2010-01-20 | 2012-02-15 | Abbott Lab | Metodos para el tratamiento del dolor |
| MX2012011821A (es) * | 2010-04-12 | 2012-11-30 | Supernus Pharmaceuticals Inc | Metodos para producir sales de viloxazina y polimorfos novedosos de las mismas. |
| US20110274628A1 (en) * | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
| CN103221411B (zh) | 2010-05-17 | 2016-05-11 | 富瑞姆制药公司 | (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型 |
| EP2598135A1 (en) | 2010-07-26 | 2013-06-05 | Gerhard Koenig | Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptor agonists in combination with acetylcholinesterase inhibitors |
| BR112013018726A2 (pt) | 2011-01-27 | 2016-10-25 | Novartis Ag | uso de ativadores de alfa 7 do receptor nicotínico de acetilcolina |
| MX2013010698A (es) | 2011-03-18 | 2014-02-17 | Novartis Ag | Combinaciones de activadores del receptor de acetil-colina nicotinico alfa-7 y antagonistas del receptor de glutamato metabotropico 5 (mglur5) para usarse en la discinesia inducida por dopamina en la enfermedad de parkinson. |
| TWI634119B (zh) | 2011-03-18 | 2018-09-01 | 美商健臻公司 | 葡萄糖神經醯胺合成酶抑制劑 |
| WO2012129262A1 (en) | 2011-03-23 | 2012-09-27 | Targacept, Inc. | Treatment of attention deficit/hyperactivity disease |
| WO2012177263A1 (en) | 2011-06-24 | 2012-12-27 | Intra-Cellular Therapies, Inc. | Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists |
| AU2012324458B2 (en) | 2011-10-20 | 2016-05-19 | Novartis Ag | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment |
| CA2872005A1 (en) | 2012-05-08 | 2013-11-14 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
| US20130317054A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Neuronal nicotinic agonist and methods of use |
| US20130317055A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Neuronal nicotinic agonist and methods of use |
| JOP20130273B1 (ar) * | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
| JPWO2014051055A1 (ja) * | 2012-09-28 | 2016-08-22 | 東レ株式会社 | キヌクリジンウレア誘導体及びその医薬用途 |
| WO2014069554A1 (ja) * | 2012-10-31 | 2014-05-08 | 東レ株式会社 | キヌクリジンアミド誘導体及びその医薬用途 |
| JP6114951B2 (ja) | 2012-12-11 | 2017-04-19 | ノバルティス アーゲー | アルファ７ニコチン性アセチルコリン受容体アクチベーターによる処置に対する応答性を予測するバイオマーカー |
| JP2016508159A (ja) | 2013-01-15 | 2016-03-17 | ノバルティス アーゲー | アルファ７ニコチン性アセチルコリン受容体アゴニストの使用 |
| KR101879920B1 (ko) | 2013-01-15 | 2018-07-18 | 노파르티스 아게 | 알파 7 니코틴성 아세틸콜린 수용체 작용물질의 용도 |
| CN105263492B (zh) | 2013-01-15 | 2018-04-10 | 诺华有限公司 | α7烟碱型乙酰胆碱受体激动剂在治疗发作性睡病中的应用 |
| WO2015168616A1 (en) * | 2014-05-02 | 2015-11-05 | Abbvie Inc. | Neuronal nicotinic agonists and methods of use |
| CA2971413A1 (en) * | 2014-12-16 | 2016-06-23 | Axovant Sciences Gmbh | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
| BR112017023821A2 (pt) | 2015-05-06 | 2018-07-31 | Leidos Biomedical Res Inc | moduladores de k-ras |
| US9724340B2 (en) | 2015-07-31 | 2017-08-08 | Attenua, Inc. | Antitussive compositions and methods |
| CN106243103B (zh) * | 2016-07-14 | 2017-11-03 | 广西师范大学 | 萘并[1，2‑h] [1，6]萘啶‑3(4H) ‑酮类化合物及其制备方法和应用 |
| CN106588926B (zh) * | 2016-12-28 | 2018-10-09 | 华东师范大学 | 一种2,7-二氮杂[3,2,1]二环辛烷及其衍生物及其合成方法和应用 |
| CN108727416B (zh) * | 2017-04-20 | 2021-03-09 | 北京大学 | 三环杂芳香体系酰胺衍生物及其制备和用途 |
| BR112019021899A2 (pt) | 2017-04-20 | 2020-08-18 | The Regents Of The University Of California | moduladores de k-ras |
| US11491150B2 (en) | 2017-05-22 | 2022-11-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| MX2022005679A (es) * | 2019-11-15 | 2022-06-27 | Yuhan Corp | Nuevos derivados que tienen una fraccion de 2,3-dihidro-1h-indeno o 2,3-dihidrobenzofurano o una sal farmaceuticamente aceptable de los mismos y composiciones farmaceuticas que los comprenden. |
| WO2021096241A1 (en) * | 2019-11-15 | 2021-05-20 | Yuhan Corporation | Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same |
| BR112022014553A2 (pt) | 2020-02-03 | 2022-09-20 | Genzyme Corp | Métodos para tratamento de sintomas neurológicos associados a doenças do armazenamento lisossômic |
| MX2023001014A (es) | 2020-07-24 | 2023-03-01 | Genzyme Corp | Composiciones farmaceuticas que comprenden venglustat. |
| BR112023022015A2 (pt) * | 2021-05-11 | 2023-12-26 | Green Cross Corp | Novos compostos que têm atividade inibidora contra glucosilceramida sintase ou sal farmaceuticamente aceitável da mesma, processos para preparar os mesmos e respectivas composições farmacêuticas |
| CN119212992A (zh) * | 2022-05-05 | 2024-12-27 | 菲利普莫里斯生产公司 | 烟碱乙酰胆碱受体配体 |
| EP4608833A1 (en) * | 2022-10-24 | 2025-09-03 | Yuhan Corporation | Novel salt of dimethyl-2,3-dihydro-1h-indene derivative and processes for preparing the same |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4203990A (en) | 1979-04-30 | 1980-05-20 | G. D. Searle & Co. | Anti-diarrheal 2-substituted quinuclidines |
| EP0353189B1 (de) | 1988-07-28 | 1994-01-12 | Ciba-Geigy Ag | Kupfer- und Nickeldihalogenidkomplexe, Verfahren zu deren Herstellung und deren Verwendung |
| EP0402056A3 (en) | 1989-06-06 | 1991-09-04 | Beecham Group p.l.c. | Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them |
| JPH03135978A (ja) | 1989-08-08 | 1991-06-10 | Merck Sharp & Dohme Ltd | 置換ピリジン、その製法、処方並びに痴呆症における使用法 |
| IN173570B (enExample) | 1989-11-23 | 1994-06-04 | Pfizer | |
| DK40890D0 (da) | 1990-02-16 | 1990-02-16 | Ferrosan As | Substituerede urinstofforbindelser, deres fremstilling og anvendelse |
| EP0492903A1 (en) | 1990-12-21 | 1992-07-01 | MERCK SHARP & DOHME LTD. | Substituted pyrazines, pyrimidines and pyridazines for use in the treatment of glaucoma |
| US5212188A (en) | 1992-03-02 | 1993-05-18 | R. J. Reynolds Tabacco Company | Method for treatment of neurodegenerative diseases |
| US5276043A (en) | 1992-04-10 | 1994-01-04 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
| US5852041A (en) | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
| WO1995003306A1 (en) | 1993-07-22 | 1995-02-02 | E.I. Du Pont De Nemours And Company | Arthropodicidal azacyclic heterocycles |
| US5510355A (en) | 1994-09-06 | 1996-04-23 | Bencherif; Merouane | Depolarizing skeletal muscle relaxants |
| US5998404A (en) | 1994-10-24 | 1999-12-07 | Eli Lilly And Company | Heterocyclic compounds and their use |
| US5616707A (en) | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
| US5597919A (en) | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
| US5824692A (en) | 1995-01-06 | 1998-10-20 | Lippiello; Patrick Michael | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
| US5604231A (en) | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
| WO1996025160A1 (en) | 1995-02-17 | 1996-08-22 | Novo Nordisk A/S | The use of heterocyclic compounds |
| US5583140A (en) | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| JPH11508540A (ja) | 1995-06-29 | 1999-07-27 | ノボ ノルディスク アクティーゼルスカブ | 新規の置換アザ環式またはアザ二環式化合物 |
| EP0853621A1 (en) | 1995-09-22 | 1998-07-22 | Novo Nordisk A/S | Novel substituted azacyclic or azabicyclic compounds |
| US5616716A (en) | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
| US5663356A (en) | 1996-04-23 | 1997-09-02 | Ruecroft; Graham | Method for preparation of aryl substituted alefinic secondary amino compounds |
| MX9706944A (es) * | 1996-09-12 | 1998-08-30 | Pfizer | Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p. |
| ZA9711092B (en) | 1996-12-11 | 1999-07-22 | Smithkline Beecham Corp | Novel compounds. |
| US5861423A (en) | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| US5811442A (en) | 1997-02-21 | 1998-09-22 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow |
| TR199902942T2 (xx) | 1997-05-30 | 2000-04-21 | Neurosearch A/S | Nikotinik ACh Resept�rlerinde kolinerjik ligandlar olarak 8-Azabisiklo(3.2.1)okt-ene ve okstan t�revleri. |
| ATE261443T1 (de) | 1997-06-30 | 2004-03-15 | Targacept Inc | 3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen |
| US5952339A (en) | 1998-04-02 | 1999-09-14 | Bencherif; Merouane | Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release |
| ES2199561T3 (es) | 1998-04-02 | 2004-02-16 | Targacept, Inc. | Derivados de azatriciclo(3.3.1.1)decano y composiciones farmaceuticas que los contienen. |
| US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| US6432975B1 (en) | 1998-12-11 | 2002-08-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| GB0010955D0 (en) | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
| US6479510B2 (en) * | 2000-08-18 | 2002-11-12 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
-
2003
- 2003-02-21 US US10/372,642 patent/US6953855B2/en not_active Expired - Lifetime
-
2004
- 2004-02-20 NZ NZ565177A patent/NZ565177A/en not_active IP Right Cessation
- 2004-02-20 PT PT04713356T patent/PT1594869E/pt unknown
- 2004-02-20 KR KR1020107026476A patent/KR101098490B1/ko not_active Expired - Fee Related
- 2004-02-20 CN CNA2007101598898A patent/CN101220026A/zh active Pending
- 2004-02-20 PL PL395717A patent/PL395717A1/pl unknown
- 2004-02-20 EP EP04713356A patent/EP1594869B9/en not_active Expired - Lifetime
- 2004-02-20 EA EA200501329A patent/EA011033B1/ru not_active IP Right Cessation
- 2004-02-20 AT AT04713356T patent/ATE381563T1/de active
- 2004-02-20 JP JP2006503737A patent/JP4828407B2/ja not_active Expired - Fee Related
- 2004-02-20 DK DK04713356T patent/DK1594869T3/da active
- 2004-02-20 AU AU2004215386A patent/AU2004215386B2/en not_active Ceased
- 2004-02-20 KR KR1020057015424A patent/KR101098481B1/ko not_active Expired - Fee Related
- 2004-02-20 PL PL395718A patent/PL395718A1/pl unknown
- 2004-02-20 KR KR1020107026477A patent/KR101098480B1/ko not_active Expired - Fee Related
- 2004-02-20 NZ NZ541794A patent/NZ541794A/en not_active IP Right Cessation
- 2004-02-20 NZ NZ565178A patent/NZ565178A/en not_active IP Right Cessation
- 2004-02-20 MX MXPA05008926A patent/MXPA05008926A/es active IP Right Grant
- 2004-02-20 PL PL378145A patent/PL378145A1/pl unknown
- 2004-02-20 WO PCT/US2004/005044 patent/WO2004076449A2/en not_active Ceased
- 2004-02-20 BR BRPI0407708-3A patent/BRPI0407708A/pt not_active IP Right Cessation
- 2004-02-20 CN CN2004800047360A patent/CN1751041B/zh not_active Expired - Fee Related
- 2004-02-20 ES ES04713356T patent/ES2300749T3/es not_active Expired - Lifetime
- 2004-02-20 DE DE602004010787T patent/DE602004010787T2/de not_active Expired - Lifetime
- 2004-02-20 CA CA2514135A patent/CA2514135C/en not_active Expired - Fee Related
-
2005
- 2005-06-20 US US11/157,119 patent/US7767193B2/en not_active Expired - Lifetime
- 2005-07-20 IL IL169797A patent/IL169797A/en not_active IP Right Cessation
- 2005-08-15 ZA ZA200506515A patent/ZA200506515B/en unknown
- 2005-08-31 NO NO20054052A patent/NO332757B1/no not_active IP Right Cessation
-
2006
- 2006-07-18 US US11/458,231 patent/US7425561B2/en not_active Expired - Fee Related
-
2008
- 2008-02-04 CY CY20081100129T patent/CY1107175T1/el unknown
- 2008-02-06 US US12/026,847 patent/US7754189B2/en not_active Expired - Fee Related
-
2009
- 2009-12-11 US US12/636,269 patent/US8143272B2/en not_active Expired - Fee Related
-
2010
- 2010-01-08 US US12/684,358 patent/US8158649B2/en not_active Expired - Fee Related
- 2010-06-04 US US12/793,773 patent/US8084462B2/en not_active Expired - Fee Related
- 2010-08-24 US US12/862,373 patent/US8124618B2/en not_active Expired - Fee Related
- 2010-08-24 US US12/862,416 patent/US8124620B2/en not_active Expired - Fee Related
- 2010-08-24 US US12/862,388 patent/US8124619B2/en not_active Expired - Fee Related
- 2010-10-04 IL IL208461A patent/IL208461A/en not_active IP Right Cessation
- 2010-10-04 IL IL208462A patent/IL208462A/en not_active IP Right Cessation
-
2011
- 2011-01-06 NO NO20110013A patent/NO332759B1/no not_active IP Right Cessation
- 2011-01-06 NO NO20110014A patent/NO332760B1/no not_active IP Right Cessation
- 2011-02-03 JP JP2011021778A patent/JP5291728B2/ja not_active Expired - Fee Related
- 2011-02-03 JP JP2011021779A patent/JP5211183B2/ja not_active Expired - Fee Related
- 2011-12-15 US US13/326,868 patent/US8541447B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0407708A (pt) | 3-substituìdo-2(arilalquila)-1-azabicicloalcanos e métodos de seu uso | |
| TW200833686A (en) | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | |
| MX2021013110A (es) | Compuestos heterociclicos como inhibidores de la cinasa ret. | |
| ATE503754T1 (de) | 1h-indol-3-carbonsäure-chinuclidin-4- ylmethylesterderivate als liganden für den nikotinischen alpha-7-acetylcholinrezeptor zur behandlung von alzheimer-krankheit | |
| NO20070347L (no) | Modulatorer av alfa7 nikotinske acetylkolinreseptorer og terapeutiske anvendelser | |
| TNSN08140A1 (enExample) | ||
| DK1176963T3 (da) | Anvendelse af dopamin-D3-receptorantagonister til fremstilling af lægemidler til behandling af nyrefunktionsforstyrrelser | |
| TW200633698A (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
| MX2021015503A (es) | Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b. | |
| IL189204A0 (en) | Heteroaryl-substituted diazatricycloalkanes, methods for its preparation and use thereof | |
| MX2010004880A (es) | Derivados heterociclicos de urea y tiourea, y metodos de uso de los mismos. | |
| NO20074977L (no) | Fuserte tiazolderivater med affinitet for histamin H3 receptoren | |
| DOP2013000009A (es) | Derivados heterociclicos fusionados como moduladores s1p | |
| TW200716599A (en) | Alkylquinoline and alkylquinazoline kinase modulators | |
| ATE384708T1 (de) | Piperazinderivate als aktivitätsmodulatoren der chemokinrezeptoren | |
| PH12020500600B1 (en) | Triazole, imidazole and pyrrole condensed piperazine derivatives and their use as modulators of mglu5 receptors | |
| UA94053C2 (ru) | Замещенные производные 3-сульфонилиндазола в качестве лигандов гидрокситриптамина-6 | |
| MX2008002158A (es) | Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6. | |
| PH12019550251A1 (en) | HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15K | Others concerning applications: alteration of classification |
Free format text: PARA INT.CL: C07D 453/00, C07D 453/02, A61P 25/00 Ipc: C07D 453/00 (2011.01), C07D 453/02 (2011.01) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 12A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2364 DE 26-04-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |